Patents Assigned to RVX Therapeutics Inc.
  • Novel Heterocyclic Compounds as Bromodomain Inhibitors
    Publication number: 20140179648
    Abstract: The present disclosure relates to compounds, which are useful for inhibition of BET protein function by binding to bromodomains, and their use in therapy.
    Type: Application
    Filed: December 19, 2013
    Publication date: June 26, 2014
    Applicant: RVX Therapeutics Inc.
    Inventors: Shuang Liu, Bryan Cordell Duffy, John Frederick Quinn, May Xiaowu Jiang, Ruifang Wang, Gregory Scott Martin, He Zhao, Bruce Francis Molino, Peter Ronald Young
  • BIARYL DERIVATIVES AS BROMODOMAIN INHIBITORS
    Publication number: 20140140956
    Abstract: The present disclosure relates to compounds, which are useful for inhibition of BET protein function by binding to bromodomains, and their use in therapy.
    Type: Application
    Filed: November 20, 2013
    Publication date: May 22, 2014
    Applicant: RVX Therapeutics Inc.
    Inventors: David John Fairfax, Gregory Scott Martin, John Frederick Quinn, Bryan Cordell Duffy, Gregory Steven Wagner, Peter Ronald Young
  • CYCLIC AMINES AS BROMODOMAIN INHIBITORS
    Publication number: 20140142102
    Abstract: The present disclosure relates to compounds, which are useful for inhibition of BET protein function by binding to bromodomains, and their use in therapy.
    Type: Application
    Filed: November 20, 2013
    Publication date: May 22, 2014
    Applicant: RVX Therapeutics Inc.
    Inventors: David John Fairfax, Bryan Cordell Duffy, Gregory Scott Martin, John Frederick Quinn, Shuang Liu, Gregory Steven Wagner, Peter Ronald Young
  • TREATMENT OF DISEASES BY EPIGENETIC REGULATION
    Publication number: 20130281397
    Abstract: The present disclosure provides non-naturally occurring polyphenol compounds that inhibit the bromodomain and extra terminal domain (BET) proteins. The disclosed compositions and methods can be used for treatment and prevention of cancer, including NUT midline carcinoma, Burkitt's Lymphoma, Acute Myelogenous Leukemia, and Multiple Myeloma; autoimmune or inflammatory diseases or conditions, and sepsis.
    Type: Application
    Filed: March 15, 2013
    Publication date: October 24, 2013
    Applicant: RVX Therapeutics Inc.
    Inventors: Kevin G. McLure, Peter Ronald Young
  • TREATMENT OF DISEASES BY EPIGENETIC REGULATION
    Publication number: 20130281396
    Abstract: The present disclosure provides non-naturally occurring polyphenol compounds that inhibit the bromodomain and extra terminal domain (BET) proteins. The disclosed compositions and methods can be used for treatment and prevention of cancer as well as sepsis, including NUT midline carcinoma, Burkitt's Lymphoma, Acute Myelogenous Leukemia, and Multiple Myeloma.
    Type: Application
    Filed: March 15, 2013
    Publication date: October 24, 2013
    Applicant: RVX Therapeutics Inc.
    Inventors: Kevin G. McLure, Peter R. Young
  • TREATMENT OF DISEASES BY EPIGENETIC REGULATION
    Publication number: 20130281399
    Abstract: The present disclosure provides non-naturally occurring polyphenol compounds that inhibit the bromodomain and extra terminal domain (BET) proteins. The disclosed compositions and methods can be used for treatment and prevention of diseases or disorders that are susceptible to administration of a BET inhibitor.
    Type: Application
    Filed: March 15, 2013
    Publication date: October 24, 2013
    Applicant: RVX Therapeutics Inc.
    Inventors: Kevin G. McLure, Peter R. Young
  • TREATMENT OF DISEASES BY EPIGENETIC REGULATION
    Publication number: 20130281398
    Abstract: The present disclosure provides non-naturally occurring polyphenol compounds that inhibit the bromodomain and extra terminal domain (BET) proteins. The disclosed compositions and methods can be used for treatment and prevention of diseases or disorders that are susceptible to administration of a BET inhibitor.
    Type: Application
    Filed: March 15, 2013
    Publication date: October 24, 2013
    Applicant: RVX Therapeutics Inc.
    Inventors: Kevin G. McLure, Peter R. Young